Lu, Chuanjun; Guo, Yueyan; Yan, Jun; Luo, Zonghua; Luo, Hai-Bin; Yan, Ming; Huang, Ling; Li, Xingshu published the artcile< Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer's Disease>, Related Products of 112-63-0, the main research area is resveratrol derivative preparation Alzheimer treatment beta amyloid aggregation inhibitor; biometal chelator resveratrol derivative Alzheimer treatment; antioxidant resveratrol derivative Alzheimer treatment.
A series of multitarget-directed resveratrol derivatives was designed and synthesized for the treatment of Alzheimer’s disease (AD). In vitro studies indicated that most of the target compounds exhibit significant inhibition of self-induced β-amyloid (Aβ) aggregation and Cu(II)-induced Aβ1-42 aggregation and acted as potential antioxidants and biometal chelators. In particular, compounds I (R = Me) (II) and I (R = H) (III) are potential lead compounds for AD therapy (II, IC50 = 7.56 μM and III, IC50 = 6.51 μM for self-induced Aβ aggregation; the oxygen radical absorbance capacity assay using fluorescein (ORAC-FL) values are 4.72 and 4.70, resp.). Moreover, these compounds are capable of disassembling the highly structured Aβ fibrils generated by self- and Cu(II)-induced Aβ aggregation. Furthermore, II crossed the blood-brain barrier (BBB) in vitro and did not exhibit any acute toxicity in mice at doses of up to 2000 mg/kg. Taken together, the data indicate that II is a very promising lead compound for AD.
Journal of Medicinal Chemistry published new progress about Alzheimer disease. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Related Products of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics